The recent approval of the anti-PD-1 monoclonal antibody pembrolizumab [41], and theragnostic antibodies targeting the prostate specific membrane antigen (anti-PSMA) to deliver radioligand therapy, such as 177Lu-PSMA, have extended the therapeutic repertoire for advanced PCa [42]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.